Tyrosine kinase inhibitors (TKI) against EGFR, such as Gefitinib, are used as targeted therapy for lung cancer with EGFR gene changes, but many tumors acquire TKI resistance after treatment. This evidence concerns the gene EGFR and lung cancer.